It is predicted that adverse drug reactions cost the NHS more than 2.2bn a year in hospital stays alone. A spokesperson for Lilly, the maker of Mounjaro, said: Patient safety is Lillys top priority
14,15,16 For semaglutide and lifestyle modification, Kim et al 14 reported an ICER of $123 000/QALY compared with lifestyle modification alone, whereas the Institute for Clinical and Economic Review 16 reported an ICER of $237 000/QALY compared with lifestyle modification alone
Thankfully, severe gastrointestinal complications related to Mounjaro use are rare
A lyophilised peptide isn't ready for research use the moment it arrives
A prescription is required from a licensed medical provider.
Obesity is a major risk factor for a range of age-related conditions, including heart disease, diabetes, and certain types of cancer